The American Cancer Society estimates there are nearly 300,000 new cases of prostate cancer every year in the U.S., and approximately one in eight men will be diagnosed with prostate cancer in their lifetime. Prostate cancer ...
10 hours ago
0
1
Novel therapeutic approaches are needed for children with diffuse midline glioma (DMG) and other recurrent high-grade central nervous system (CNS) tumors, aggressive brain cancers with poor prognoses. A type of immunotherapy ...
10 hours ago
0
0
Hepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms. The tumor microenvironment plays a pivotal role in fostering ...
10 hours ago
0
0
A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel ...
May 21, 2024
0
405
When cells become tumor cells, their metabolism changes fundamentally. Researchers at the University of Basel and the University Hospital Basel have now demonstrated that this change leaves traces that could provide targets ...
May 21, 2024
0
25
Investigators have discovered new mechanisms underlying the diversity of characteristics within a single tumor, as well as treatment resistance, in the most common type of primary central nervous system tumor, according to ...
May 20, 2024
0
22
For many patients with a deadly type of brain cancer called glioblastoma, chemotherapy resistance is a big problem.
May 20, 2024
0
21
Glioblastoma is an aggressive brain cancer that has no cure. A recent chart study of patients with glioblastoma found that taking chemotherapy in the morning was associated with a three- to six-month increase in median survival.
May 20, 2024
0
45
Roughly one in five cancer patients benefit from immunotherapy—a treatment that harnesses the immune system to fight cancer. Such an approach to beating cancer has seen significant success in lung cancer and melanoma, among ...
May 17, 2024
0
62
A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.
May 17, 2024
0
22
